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Abstract
Background: Medialization thyroplasty and injection laryngoplasty are widely accepted treatment options for unilateral
vocal fold paralysis. Although both procedures result in similar clinical outcomes, little is known about the corresponding
medical care costs. Medialization thyroplasty requires expensive operating room resources while injection laryngoplasty
utilizes outpatient resources but may require repeated procedures. The purpose of this study, therefore, is to quantify the
cost differences in adult patients with unilateral vocal fold paralysis undergoing medialization thyroplasty versus injection
laryngoplasty.
Study design: Cost minimization analysis conducted using a decision tree model.
Methods: A decision tree model was constructed to capture clinical scenarios for medialization thyroplasty and injection
laryngoplasty. Probabilities for various events were obtained from a retrospective cohort from the London Health Sciences
Centre, Canada. Costs were derived from the published literature and the London Health Science Centre. All costs were
reported in 2014 Canadian dollars. Time horizon was 5 years. The study was conducted from an academic hospital
perspective in Canada. Various sensitivity analyses were conducted to assess differences in procedure-specific costs and
probabilities of key events.
Results: Sixty-three patients underwent medialization thyroplasty and 41 underwent injection laryngoplasty. Cost of
medialization thyroplasty was C$2499.10 per patient whereas those treated with injection laryngoplasty cost C$943.19.
Results showed that cost savings with IL were C$1555.91. Deterministic and probabilistic sensitivity analyses suggested cost
savings ranged from C$596 to C$3626.
Conclusions: Treatment with injection laryngoplasty results in cost savings of C$1555.91 per patient. Our extensive
sensitivity analyses suggest that switching from medialization thyroplasty to injection laryngoplasty will lead to a minimum
cost savings of C$596 per patient. Considering the significant cost savings and similar effectiveness, injection laryngoplasty
should be strongly considered as a preferred treatment option for patients diagnosed with unilateral vocal fold paralysis.
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Background
The aim of treatment for unilateral vocal fold paralysis
(UVFP) is, firstly, to decrease aspiration, and secondly, to
improve voice quality. One treatment paradigm is mediali-
zation of the paralysed vocal fold to allow for contact with
the mobile vocal fold. Two options for medialization
include Type 1 medialization thyroplasty (MT) and injec-
tion laryngoplasty (IL). MT, as described by Isshiki et al., is
considered the gold standard treatment and involves
permanent medialization of the vocal fold with an alloplas-
tic stent in the paraglottic space [1]. However, with the
development of reliable injectable soft tissue fillers and dis-
tal chip flexible endoscopes, office-based IL has become a
new alternative [2]. An injectable filler, such as methylcellu-
lose, collagen, or calcium hydroxylapatite, is used to media-
lize the vocal fold via percutaneous or transoral injection.
Since MTand IL utilize the same medialization treatment
paradigm, these techniques are often applied in similar clin-
ical scenarios. Outcomes between treatment options have
been compared and have been found to yield similar
clinical outcomes [3–6]. MT offers a permanent solution
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but requires operating room time and sedation. In contrast,
IL is performed in the outpatient clinic setting. However,
the soft tissue fillers are resorbed over time and treatment
may require multiple injections over one’s lifetime [7].
Given the current fiscal constraints in our health care
system, the cost of both procedures should be considered
when deciding on the ideal intervention for UVFP. The pur-
pose of this study is therefore to quantify the cost differences
between MTand office-based IL in adults with UVFP.
Methods
This economic analysis was conducted from the London
Health Sciences Centre (LHSC) perspective-a tertiary
academic hospital in Canada. All costs were reported in
2014 Canadian dollars. A 5-year time horizon was used.
The discount rate was set at 5% to account for inflation
and interest over time [8]. Time to relapse of IL was set
to 1 year as the expected lifespan of calcium hydroxylap-
atite is between 1 to 2 years [4].
Decision analytic model
A decision tree model, consistent with the usual treatment
pathways for MT and IL for patients presenting with UVFP,
was developed to perform our cost-minimization analysis
(Fig. 1). Analysis was conducted using TreeAge Pro 2009
software (TreeAge Software, Inc., Williamstown, MA).
Medialization procedures
MT was performed in the operating room under light
sedation and local anesthesia. A nasopharyngoscope was
used for visualization of the vocal folds preoperatively and
left in place intra-operatively to confirm medialization. The
standard thyroplasty approach using the Montgomery®
Thyroplasty Implant System (Boston Medical Products,
Westborough, MA) was employed, as described by
Montgomery and Montgomery [9]. Patients were brought
to the post-operative recovery unit following the procedure.
Patients were stratified by risk for post-operative compli-
cations as described by Zhao et al. and admitted or
discharged home accordingly [10]. Reasons for admission
include previous neck radiation or surgery, and other co-
morbidities such as myocardial infarction and stroke.
IL was performed in an outpatient, hospital-based
Otolaryngology-Head and Neck Surgery clinic. The patient
was positioned in the examination chair in the semi-
recumbent position. The cricothyroid approach was most
preferred, but transthyrohyoid membrane or transthyroid
approaches were also used as indicated. Local anesthesia
was infiltrated into the anterior neck soft tissues overlying
the cricothyroid membrane and the airway. Under direct vi-
sion with the nasopharyngoscope, the needle was advanced
to the thyroarytenoid muscle and an injection of calcium
hydroxylapatite (RadiesseTM Voice, Merz Aesthetics Inc.,
San Mateo CA) was completed until the paralyzed vocal
fold was medialized. Patient vocalization confirmed media-
lization. The patient was monitored in the clinic waiting
area for at least 30 min, then discharged home.
Probabilities
Probabilities for model parameters were derived from a
retrospective cohort of patients from LHSC. Patients were
accrued after approval from the institution ethics review
board (Institutional Research Ethics Board #105711). Con-
secutive patients treated by four Otolaryngology-Head and
Neck surgeons with MT or IL for UVFP from April 2008
to April 2014 were eligible for inclusion. Other inclusion
criteria were: 1) adult over the age of 18, 2) patients were
medically eligible for both treatment modalities, and 3) at
least one post-procedural follow-up. Patients were excluded
if there was any possibility of resolution of UVFP as recov-
ery may be mistaken for success of the procedure and skew
probability of resolution of symptoms in the model. These
included patients with idiopathic UVFP with a duration of
less than 1 year at the time of presentation. Selection of
MT versus IL was a joint decision by the surgeon and pa-
tient, considering patient preference and surgeon comfort.
Date of decision to treat was set as the date of obtaining
consent for the procedure.
Patient diagnosis, age, gender, and intervention were re-
corded. Post-procedural swallowing and voice symptoms
were recorded at 1 month. Need for repeat or revision
procedure and complications were assessed. Gastrostomy
tube dependence rate was recorded where available.
Patient demographics
A total of 228 patients were screened for inclusion via
retrospective review. One hundred four patients met the
inclusion and exclusion criteria. Sixty-three patients
underwent MT whereas 41 underwent IL. Patient demo-
graphics and clinical characteristics are reported in Table 1.
Patient demographic characteristics were compared using
the paired t-test and chi-squared test.
Probabilities for medialization thyroplasty
Of the 63 patients initially treated with MT, 53 (84.1%)
were asymptomatic at 1 month. Four patients continued to
have voice complaints. Six patients reported both voice and
swallowing symptoms. Two patients, one with voice com-
plaints and one with voice and swallowing complaints,
underwent revision MT. The patient with initial voice com-
plaints was treated successfully with revision MT. However,
the patient with initial voice and swallowing complaints
remained symptomatic, underwent a second revision sur-
gery, and was subsequently asymptomatic. As a second
revision surgery is rare in the clinical setting, this was not
included in the base case analysis, but the impact of its
inclusion is discussed in the sensitivity analysis. Thirty-eight
patients (60.3%) were admitted for overnight stay based on
Tam et al. Journal of Otolaryngology - Head and Neck Surgery  (2017) 46:14 Page 2 of 10
criteria of Zhao et al. [10] All patients undergoing revision
MT were admitted due to prior neck surgery.
Probabilities for injection laryngoplasty
Forty-one patients underwent IL. Eighteen patients
(43.9%) were asymptomatic at 1 month. Eight patients
continued to have voice complaints and 15 patients
continued to have voice and swallowing complaints at
follow-up. Of these patients, three underwent repeat IL.
Two of these patients were subsequently asymptomatic,
but one continued to have voice complaints. This patient
was consented for MT but passed away prior to the
procedure due to a prior lung neoplasm.
Six patients had satisfactory initial results from IL but
became symptomatic and underwent subsequent MT.
Time from IL to MT was a mean of 18 months. All
patients were asymptomatic following MT. No patients
were admitted following IL.
Fig. 1 Decision Tree of Cost Minimization comparing Medialization Thyroplasty and Injection Laryngoplasty. The square represents the initial decision
to undergo MT or IL after the identification of UVFP. Circles represent chance events, and triangles represent terminal nodes beyond which no further
interventions and costs occurred. One month following the procedure (MT or IL), patients were stratified into 3 groups based on the post-procedural
outcomes: voice symptoms (V), voice and swallowing symptoms (V & S), and asymptomatic (Asymp). There were no patients who complained of
swallowing symptoms without voice symptoms. Patients with symptoms (V or V & S) after the implementation of initial IL have three possible paths:
immediate revision IL (Revision IL), MT (Switch to MT), or observation if the patient was satisfied despite their symptomology (Satisfactory). Due to the
temporary nature of the fillers used for IL, patients who were initially satisfied with their treatment despite symptomology could have three possible
paths: repeat IL (2nd IL), MT (Switch to MT), or observation if the patient remained satisfied despite their symptoms (Remain Satisfactory). Similarly,
patients who were asymptomatic after the initial IL could have three possible paths: relapse after the fillers are resorbed over time and have a repeat IL
(2nd IL), undergo MT (Switch to MT), or remain asymptomatic (Remain Asymp). MT Subtree: For patients with symptoms (V or V & S) after MT, there
were two possible paths: immediate revision MT (Revision MT), or observation if the patient was satisfied despite their symptomology (Satisfactory). For
patients who were asymptomatic after MT, there was no further intervention as of MT is considered permanent
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Costs
Where available, LHSC costs were utilized. Only direct
medical care costs (costs for personnel, equipment, and
materials) were considered in the base case analysis to
reflect LHSC’s perspective. Indirect costs were included
in the scenario analysis to provide a societal perspective.
Costs for medialization thyroplasty
Cost for MT consisted of four components: surgeon,
anesthesiologist, operating room and recovery personnel,
and equipment costs (Table 2). Surgeon and
anesthesiologist costs were based on the schedule of
benefits published by the Ontario Health Insurance
Program (OHIP) [11]. Ontario operates as a single payer
system and this government published list consists of
uniform fees paid for physician services throughout the
province. Operating room and recovery unit personnel
costs were calculated by the duration of each procedure
at LHSC’s rate of C$5.23/min. Material costs were based





Mean Age 61.5 70.4 p = 0.003a
Males (%) 37 (57.8%) 27 (63.9%) p = 0.466
Voice Complaints (%) 63 (100%) 41 (100%) p = 1.000
Swallowing Complaints (%) 28 (44.4%) 21 (51.2%) p = 0.499








astatistically significant with α <0.05
Table 2 Parameter Table - Base Case
Parameter Base case Reference
Probabilities a (%)
Having a voice issue right after the initial MT 6.4 LHSC Datad
Undergoing revision MT for patients with voice issue after the initial MT 25.0 LHSC Datad
Having a voice and swallowing issue right after the initial MT 9.5 LHSC Datad
Undergoing revision MT for patients with voice and swallowing issue after the initial MT 16.7 LHSC Datad
Having a voice issue right after the initial IL 19.5 LHSC Data4
Having a voice and swallowing issue right after the initial IL 36.6 LHSC Datad
Undergoing revision IL for patients with voice issue after the initial IL 37.5 LHSC Datad
Having a voice issue after the revision IL for patients with voice issue after the initial IL 33.3 LHSC Datad
Switching to MT if asymptomatic right after the 1st IL but relapse over time 33.3 LHSC Datad
Admission after MT 60.3 LHSC Datad
Direct costs ($):
Costs components for MT b
Surgeon 632.85 [11]
Nursing and OR aides 325.38 LHSC Datad
Supplies 316.42 LHSC Datad
Anesthesia 165.46 [11]
Inpatient stay if admitted after a MT c 1,595.78 LHSC Data4





Nursing staff 5.42 [12]
Discount rate 5% [1]
Time to relapse 1 year [2]
a Only non-zero probabilities are listed. All probabilities for the remaining branches in the model are zero
b Revision MT was assumed to cost the same as initial MT
c Assumed rate of inpatient stay after MT is the same for patients with or without post-surgery symptoms
d Based on London Health Sciences Centre (LHSC) retrospectively collected patient cohort
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on the last 12 cases performed at the LHSC as prior data
were not available. Total cost of MT was C$1440.11. Re-
vision MT was assumed to cost the same as initial MT.
Inpatient stay following MT was C$1477.58/day based
on the mean cost of postoperative stay at LHSC. Mean
length of stay was 1.08 days. As 60.3% of all patients
undergoing initial MT were admitted, an average
inpatient stay cost of C$962.26 was included in the cost
of MT. All revision MT patients were inpatients, and an
average inpatient stay cost of C$1595.78 was added to
the cost of revision MT.
Costs for injection laryngoplasty
The cost for IL consisted of three components: surgeon,
personnel, and equipment costs (Table 2). Surgeon costs
were determined by the OHIP Schedule of Benefits [11].
Personnel costs included clinic nursing costs. Average
hourly wage as per the Ontario Nursing Association agree-
ment was multiplied by the average length of time for injec-
tion (4.86 min) [12]. This was added to an average 5 min
preparation time for room set up and clean up for a total
duration of procedure of 9.86 min. All patients, regardless
of undergoing MT or IL, would require initial consultation
and consent in the clinic. Therefore, this cost was consid-
ered equal between both groups and not included in the
cost calculations. Equipment costs were based on the insti-
tutional pharmacy and the healthcare materials manage-
ment services department. Cost for the nasopharyngoscope
and processing were obtained from the hospital and
included processing time which was timed at an average of
6.5 min, multiplied by an average technician wage of C$22/
h [13]. Following the procedure, all patients recovered in
the clinic waiting area. This was during an active clinic and
did not require any special personnel or equipment. There-
fore, no cost was associated with patient recovery time.
Total cost for an IL was C$567.24.
Complications
One patient suffered from a postoperative hematoma
following MT. This required a return visit to the operating
room. While in the hospital, this patient experienced urin-
ary retention requiring a longer hospital stay of 4 days.
There were no complications following IL. Complication
probabilities were set to zeros in the model in order to
avoid undue influence of one special case in the MTarm.
Sensitivity analysis
Deterministic and probabilistic sensitivity analyses were
conducted to account for variability in the input param-
eters presented in Tables 3 and 4. One-way sensitivity
analyses were conducted for all costs with a known
range, for a discount rate of 3 and 10%, an IL effect dur-
ation of 2 years and the percent of patients undergoing
repeat IL (Table 4).
Scenario analysis was conducted to investigate the soci-
etal cost of MT versus IL. Loss of productivity while await-
ing a procedure for UVFP was calculated as an indirect
cost. Median wait time was used for scenario analysis as
the range of wait times was wide (9-330 days). The average
wage for each age group was calculated according to
Statistics Canada assuming an average 8 h/day [14].
Assuming no patients could work during wait time for
their procedure, the estimated productivity loss is reported
in Table 5. Roy et al. found that 4.3% of patients were un-
able to work with their voice disturbance [15]. Productiv-
ity losses were calculated based on age-weighted average
according to the proportions in Table 4. Productivity loss
for MT was C$507.96 and IL C$26.58. A second scenario
analysis was conducted to account for the impact of the
patient who underwent two revision MTs.
Probabilistic sensitivity analysis using a Monte Carlo
simulation was performed on direct costs. A beta distribu-
tion was used for each probability (Table 3) while a gamma
distribution was used for each cost component (Table 5).
Results
Base case analysis
Probabilities and costs associated with the base model
are presented in Table 2. Base case analysis showed that
patients treated with MT was C$2499.10, compared to
C$943.19 when treated with IL. Cost savings with the IL
procedure was C$1555.91 per patient compared to MT.
Sensitivity analyses
One-way sensitivity analysis
Costs with variances are summarised in Table 5. Param-
eters compared for sensitivity analysis including discount
rate and relapse rate are summarised in Table 4. Cost
savings ranged from C$974.00 to C$1799.00, all favour-
ing IL. These savings persisted even if all patients
initially undergoing IL underwent a repeat IL. All one-
way sensitivity analyses results are presented in Fig. 2.
Scenario analysis
Scenario analysis was conducted to account for the im-
pact of productivity loss during the wait time for treat-
ment. Assuming a 4.3% inability to work, cost of MT
was C$3007.07 compared to C$1042.43 for IL. Cost sav-
ings was C$1964.64. Second scenario analysis accounting
for the patient who underwent two revision MTs found
the cost for initial treatment with MT increased to
C$2547.27 and the cost savings increased to C$1604.08.
Probabilistic sensitivity analysis
Parameters utilized to derive beta distributions and
gamma distributions are presented in Tables 3 and 5,
respectively. Minimum cost savings with the IL proced-
ure was C$596 while the maximum cost savings was
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C$3626. The distribution of cost savings of the probabil-
istic sensitivity analyses is presented in Fig. 3.
Discussion
Many different treatment options exist in the
Otolaryngologist-Head and Neck surgeon’s armamentarium
for UVFP. MTand IL both have the common goal of media-
lization of the affected vocal fold to facilitate contact with the
unaffected side. Though several studies investigated the effi-
cacy of both techniques, this is, to our knowledge, the first
direct comparison of costs between MT and IL procedures.
This study shows that there are cost savings when patients
are treated initially with IL with a potential cost savings of
C$1555.91 per patient. Sensitivity analyses demonstrated the
robustness of this conclusion, with probabilistic sensitivity
analysis showing cost savings from C$596 to C$3626 all
favouring the IL procedure. Hillel et al. published a study
investigating costs differences in patients undergoing laser
photoablation of laryngeal lesions in the endoscopy suite ver-
sus the operating room and found a result of significant cost
savings in the endoscopy room setting [16]. This bolsters our
finding that moving procedures from the operating room to
the outpatient setting results in significant cost savings.
In this cohort of patients, only 43.9% of patients were
asymptomatic after IL. This cohort includes the cohort of
patients first treated at LHSC with IL. Laryngeal injection
may not be a familiar technique to some surgeons and the
lower success rate may be due to a learning curve for IL.
As well, persisting voice complaints despite adequate IL
may be due to other aspects of voice production such as
breath support as neoplastic causes for UVFP (such as lung
cancer) represented the majority of included patients.
Rosen et al. reported on their findings in a multi-centred
prospective trial of IL with calcium hydroxylapatite in pa-
tients with glottic insufficiency [17]. Of the 63 patients
treated, 81% patients reported their voice to be significantly,
greatly, or somewhat improved at 12 months. However,
only 36 of those patients had a diagnosis of UVFP.
Improvements in the success of IL would likely decrease
the need for revision procedures, further decreasing the
cost of initial treatment with IL. Due to the possible vari-
ability of operator success with IL, sensitivity analysis was
completed demonstrating that even if 100% of patients
Table 3 Probabilities for Sensitivity Analyses a
Probabilities b Base case value (%) Parameters for Beta distributions for PSAc
α d β e
Having a voice issue right after the initial MT 6.4 4 59
Undergoing revision MT for patients with voice issue after the initial MT 25.0 1 3
Having a voice and swallowing issue right after the initial MT 9.5 6 57
Undergoing revision MT for patients with voice and swallowing issue after
the initial MT
16.7 1 5
Having a voice issue right after the initial IL 19.5 8 33
Having a voice and swallowing issue right after the initial IL 36.6 15 26
Undergoing revision IL for patients with voice issue after the initial IL 37.5 3 5
Having a voice issue after the revision IL for patients with voice issue after
the initial IL
33.3 1 2
Switching to MT if asymptomatic right after the 1st IL but relapse over time 33.3 6 12
Admission after MT 60.3 38 25
Having a voice issue right after the initial MT 4.3 [15]
a All probabilities are derived from the LHSC data set except the probability of having voice issue right after the initial MT
b Only non-zero probabilities are listed. All probabilities for the remaining branches in the model are zero
c PSA: probabilistic sensitivity analysis
d The parameter α for beta distribution equals the number of occurrence
e The parameter β for beta distribution equals the difference of sample size and number of occurrence
Table 4 Parameters used for Sensitivity and Scenario Analysis
Other Parameters Base Case Low Value High Value Reference
Discount rate 5% 3% 10% [1]



















a The proportions of different age groups are used in the scenario analysis
only in order to calculate the productivity loss as the indirect costs
b Based on London Health Sciences Centre (LHSC) retrospectively collected
patient cohort
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treated with IL required a repeat injection, initial treatment
with IL would continue to be more economical.
The lifespan of calcium hydroxylapatite is between 1
to 2 years. In this study, mean time from IL to further
treatment was 18 months, which is consistent with the
findings by Shen et al. [4] Our base case analysis and
sensitivity analysis analyzed costs for both a 1 and 2 year
lifespan, demonstrating cost savings with patients under-
going IL in both scenarios. In this cohort, 66.7% patients
who were initially asymptomatic after IL did not require
further treatment within a 5-year time horizon. Prendes
et al. found that those with UVFP had effects of IL with
a temporary agent longer than the expected lifespan of
the injected material [18]. The mechanism of this lasting
effect is unclear. However, considering many patients
present with UVFP due to neoplastic processes or injury
during treatment of neoplastic processes, the 2 year or
longer treatment effect may be an adequate length of
effectiveness for many patients. It is also possible that
the gradual resorption of the injected material allows for
compensation from the contralateral vocal fold in some
patients, alleviating the need for repeat treatments.
Complications
Only one complication occurred in our cohort. Due to
the unusual nature of this complication, it was not in-
cluded in our analysis. As the only complication
occurred in the MT group, inclusion of the costs of this
Table 5 Costs in 2014 Canadian Dollars for Sensitivity Analyses
Costs Base Case Standard
Deviation
One-Way Sensitivity Analysis Parameters for Gamma
distributions for PSA
References
Low Value High Value α a β b
Direct costs:
Costs components for MT c
Surgeon 632.85 [11]
Nursing and OR aides 325.38 104.30 118.49 597.61 9.7315 0.0299 LHSC Dataf
Supplies 316.42 175.44 167.70 525.11 3.2529 0.0103 LHSC Dataf
Anesthesia 165.46 32.72 118.28 266.14 25.5637 0.1545 [11]
Inpatient stay if admitted after MT d 1,595.78 635.36 6.3083 0.0040 LHSC Dataf
Costs components for IL
Equipment (CaHa) 305.71 285.97 325.45 LHSC Dataf
Physician 256.11 [11]




Productivity loss for MT if all
patients cannot work during
waiting time
Age 15–24 29666.40 [14]
Age 25–54 32913.36 [14]
Age 55–65 17677.44 [14]
Age 66+ 0 [14]
Productivity loss for IL if all
patients cannot work during
the waiting time
Age 15–24 0 [14]
Age 25–54 2796.56 [14]
Age 55–65 0 [14]
Age 66+ 0 [14]
a The parameter α for a gamma distribution is calculated by mean2/variance
b The parameter β for a gamma distribution is calculated by variance/mean
c Revision MT was assumed to cost the same as initial MT
d We assumed inpatient stay if admitted after a MT is the same for patients with or without post-surgery symptoms
e The base case values of indirect costs are used in the scenario analysis only
f Based on London Health Sciences Centre (LHSC) retrospectively collected patient cohort
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complication would not have changed the main conclu-
sions. Abraham et al. found a 14% complication rate in
MT, including transient edema, hematoma, infection,
extrusion, and airway issues [19]. Mathison et al. found
that 19.1% of patients had complications from IL, in-
cluding aborted procedure, vasovagal reaction, rapid re-
sorption of the injected material, vocal fold hemorrhage,
and superficial lamina propria injection. All these
complications were self-limited and did not require
hospitalization, limiting their associated costs [20].
Limitations and future directions
This study relies on patient-reported symptoms of voice
or swallowing complaints. Patients were treated by four
surgeons and data were accrued retrospectively, there-
fore objective measures such as maximum phonation
time or Voice Handicap Index were not reliably
recorded. However, in this cost analysis, the major deter-
minant of increased cost is the need for a second
procedure-the necessity of which is primarily driven by
the subjective complaints of the patient. Therefore, while
imperfect, patient-reported outcomes are a useful
predictor for cost in a study such as this.
Probability parameters rely on the institutional cohort.
This allows for increased homogeneity of the data but it
limits the sample size. A literature search of studies
reporting outcomes following MT or IL showed signifi-
cant variability in the reported outcome measures and
not all parameters were available. As a result of the
smaller sample size, many of the probabilities on the
decision tree were set to zero.
A larger cohort of patients would allow for capturing
rare complications and the associated transition prob-
abilities as well as costs. Our cohort also included many
Fig. 3 Results of Probabilistic Sensitivity Analysis: Distribution of Cost Savings. Generated from cost savings (when switching from initial treatment
with medialization thyroplasty to initial treatment with injection laryngoplasty) from 1000 trials in the probabilistic sensitivity analysis
Fig. 2 Tornado Diagram Demonstrating Results of the One-Way Sensitivity Analysis. Abbreviations: IL:injection laryngoplasty; MT: medialization
thyroplasty; OR: operating room
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aetiologies for UVFP. Therefore, these findings should
be further validated in other UVFP presentations and
patient populations. As well, differing techniques in IL
and MT or other management strategies may yield
different results. In particular, the patients in this study
did not have access to voice therapy with a speech
language pathologist (SLP) through LHSC and thus
would need to seek SLP services outside of our institu-
tion. Therefore, costs related to SLP services were not
included in our analysis. Applicability of our findings to
a practice setting with access to SLP services may be
limited.
A longer follow-up period and time horizon would
potentially capture more treatment failures and revision
procedures to determine the long-term costs of MT ver-
sus IL. However, many of the patients included in our
cohort developed UVFP due to neoplastic processes,
limiting the duration of follow-up.
This study focused on institutional costs of IL and MT
procedures. Indirect or societal costs were not available,
hence we investigated the influence of productivity
losses using aggregate data from Statistics Canada.
Although our study is unable to offer definite conclu-
sions regarding societal cost-savings, it is still relevant
from a hospital perspective as the direct costs are rele-
vant to hospital’s budget. All costs and parameters in
this model were obtained from the LHSC perspective,
part of a single payer Canadian system. While this in-
creases the uniformity of costs between patients and the
results are likely to be similar across Canadian hospitals,
replicability of these findings in different payer systems
may be limited. As well, all surgeons at this centre uti-
lized the Montgomery® Thyroplasty Implant System for
MT and calcium hydroxylapatite for IL. Different equip-
ment preferences at different centres may yield varying
results. However, our findings showed large cost savings
in favour of IL, the robustness of which was shown in
our probabilistic sensitivity analysis.
Conclusions
Based on this cost-minimization analysis, initial treat-
ment with IL results in C$1555.91 more cost savings
per patient than initial treatment with MT at a 5-year
time horizon in the base case analysis. Deterministic
and probabilistic sensitivity analyses and a scenario
analysis are consistent in showing that initial treat-
ment with IL is less costly than MT. Specifically,
switching from MT to IL will result in a minimum
cost savings of C$596 per patient. Though our find-
ings reflect the experience at a single Canadian centre,
we expect these cost savings to be corroborated in a
variety of different environments given the marked
difference in cost between MT and IL.
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